Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03600441 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03600441 · ClinicalTrials.gov record · last posted 2025-04-10

Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma

Study acronym: FORERUNNER
StatusActive, Not Recruiting
PhasePhase 2
Started2018-08-27
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.

Amendment record 16 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 16 times since 2018-07-24; most recent amendment 2025-04-09. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2019-07-09
Status change Recruiting→Active, Not Recruitingv12
2018-08-29
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT03600441
Lead Sponsor Xynomic Pharmaceuticals, Inc.
Conditions Follicular Lymphoma
Enrollment 139 participants
Start Date 2018-08-27
Primary Completion 2027-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-10